Startups
Pioneers in cardiac gene therapy | Developing novel treatments for common and rare diseases | Using bioengineered human heart assays
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 14, 2024 | MEDERA’S SARDOCOR ANNOUNCES FAST TRACK DESIGNATION AND DOSING OF 3 PATIENTS IN FIRST-IN-HUMAN HFpEF GENE THERAPY TRIAL | BOSTON, MA, UNITED STATES, February 14, 2024 /EINPresswire.com/ -- • Heart failure is a global pandemic with an estimated 64.3 million cases worldwide. • Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart fail... |
| Nov 21, 2023 | MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR | MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR WITH HEART FAILURE FOR PRECISION MEDICINE BOSTON, MASSACHUSETTS, UNITED STATES, November 21, 2023 /EINPresswire.com/ -- M... |
Reviews 0
FAQ about Sardocor
What has the press written about Sardocor?
Parsers VC has collected 3 articles mentioning Sardocor, among them “MEDERA’S SARDOCOR ANNOUNCES FAST TRACK DESIGNATION AND DOSING OF 3 PATIENTS IN FIRST-IN-HUMAN HFpEF GENE THERAPY TRIAL” (Feb 14, 2024) and “MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR” (Nov 21, 2023).
Is Sardocor still active?
Sardocor is probably closed: its latest activity on Parsers VC dates from Feb 28, 2024.